SCHEMBL982426

SCHEMBL982426

NNC(=Nc1cccc(Cl)c1Cl)c1cccnc1N

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S100B P04271 1/20 0.41
ITGB3 P05106 1/20 0.41
ITGAV P06756 1/20 0.41
NAPRT Q6XQN6 1/20 0.39
ALDH1A1 P00352 2/20 0.38
IDO1 P14902 2/20 0.37
PRKCI P41743 2/20 0.36
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
KMT2A Q03164 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
DHODH Q02127 1/20 0.34
PABPC1 P11940 1/20 0.34
EIF4H Q15056 1/20 0.34
GAA P10253 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
JAK2 O60674 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL982684 0.87 NAPRT (0.37) NAPRTALDH1A1IDO1PRKCIDHODH
SCHEMBL985510 0.79 REV1 (0.39) NAPRTALDH1A1IDO1PRKCIKDM4E
SCHEMBL982424 0.74 GAA (0.46) NAPRTALDH1A1PRKCIKDM4EMEN1
SCHEMBL982425 0.74 GAA (0.46) NAPRTALDH1A1PRKCIKDM4EMEN1
SCHEMBL985740 0.68 GAA (0.64) NAPRTALDH1A1PRKCICYP1A2CYP2C19
SCHEMBL982682 0.67 PABPC1 (0.40) NAPRTPRKCIMEN1KMT2ADHODH
SCHEMBL982681 0.67 PABPC1 (0.40) NAPRTPRKCIMEN1KMT2ADHODH
SCHEMBL11946796 0.67 PABPC1 (0.40) NAPRTPRKCIMEN1KMT2ADHODH
SCHEMBL2076143 0.67 NAPRT (0.40) NAPRTALDH1A1PRKCICYP1A2CYP2C19
SCHEMBL10767060 0.66 ALDH1A1 (0.55) ALDH1A1IDO1MEN1KMT2ASIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232406-B2 c-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-31 US disclosed
US-7872031-B2 c-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-18 US disclosed
EP-2004625-B1 C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS VERTEX PHARMA (US) 2009-12-30 EP disclosed
US-20070254868-A1 C-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254868-A1 C-MET protein kinase inhibitors MET, PRKCH, ABL1 S100B 3295/4885ITGB3 2390/4885ITGAV 4010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.